LD-2 disclosure · 2nd Quarter - Report
COHERUS BIOSCIENCES, INC.
Client
- Name
- COHERUS BIOSCIENCES, INC.
- Location
- California · United States of America
Registrant
- Description
- lobbying, advocacy, pharmaceutical company
- Location
- Redwood City, California, United States of America
Lobbying activities
2 issuesHealth Issues
Domestic Manufacturing Medicare implications on biosimilars, Part D reform Drug Rebate Reform Appropriations pertaining to American Made preference HHS Supply Chain Readiness HHS Biosimilar Uptake American-Made, Security of the American Pharmaceutical and Medical Supply Chain 117 - S.2082 - Manufacturing API, Drugs, and Excipients (MADE) in America Act S.3311 - American Made Pharmaceuticals Act of 2023 FDA foreign inspections ASPR/BARDA funding and policy Interchangeability of biosimilars legislation
LobbyistsDAVID SANDERS · BEN KENNEY · ALI MCBRIDE
Covered position (DAVID SANDERS): Legislative Affairs, Dept of Commerce, US Patent and Trademark Office (2005-2007) Legislative Assistant, Representative Marsha Blackburn (2002-2004) Legislative and Press Intern, Senator Fred Thompson (2000)
Covered position (BEN KENNEY): Director of Strategic Communications and External Affairs, Centers for Medicare and Medicaid Services (2018-2021), Associate Administrator, General Services Administration (2017-2018), Legislative Aide, U.S. Sen. Daniel R. Coats (2011-2012)
TargetedSENATE · HOUSE OF REPRESENTATIVES · Executive Office of the President (EOP) · White House Office · Natl Security Council (NSC) · Office of Management & Budget (OMB) · Office of Science & Technology Policy (OSTP) · Defense, Dept of (DOD) · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA) · Centers For Medicare and Medicaid Services (CMS)
Government Issues
Implementation of Buy American and Supply Chain Executive Orders American-Made Policies American-Made Supply Chain Security of the American Pharmaceutical and Medical Supply Chain Biosimilars Policy BARDA funding ASPR funding ARPA-H funding and implementation Industrial Supply and Financing IRA implementation Part D biosimilars utilization